|
1 Indications And Usage Bavencio Is A Programmed Death Ligand-1 (Pd-L1) Blocking Antibody Indicated For: Merkel Cell Carcinoma (Mcc) Adults And Pediatric Patients 12 Years And Older With Metastatic Mcc. This Indication Is Approved Under Accelerated Approval Based On Tumor Response Rate And Duration Of Response. Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In Confirmatory Trials. ( 1.1 , 14.1 ) Urothelial Carcinoma (Uc) Maintenance Treatment Of Patients With Locally Advanced Or Metastatic Uc That Has Not Progressed With First-Line Platinum-Containing Chemotherapy. ( 1.2 , 14.2 ) Patients With Locally Advanced Or Metastatic Uc Who: Have Disease Progression During Or Following Platinum-Containing Chemotherapy. ( 1.2 14.2 ) Have Disease Progression Within 12 Months Of Neoadjuvant Or Adjuvant Treatment With Platinum-Containing Chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (Rcc) First-Line Treatment, In Combination With Axitinib, Of Patients With Advanced Rcc. ( 1.3 , 14.3 ) 1.1 Metastatic Merkel Cell Carcinoma Bavencio (Avelumab) Is Indicated For The Treatment Of Adults And Pediatric Patients 12 Years And Older With Metastatic Merkel Cell Carcinoma (Mcc). This Indication Is Approved Under Accelerated Approval Based On Tumor Response Rate And Duration Of Response. Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In Confirmatory Trials [See Clinical Studies (14.1) ] . 1.2 Locally Advanced Or Metastatic Urothelial Carcinoma First-Line Maintenance Treatment Of Urothelial Carcinoma Bavencio Is Indicated For The Maintenance Treatment Of Patients With Locally Advanced Or Metastatic Urothelial Carcinoma (Uc) That Has Not Progressed With First-Line Platinum-Containing Chemotherapy [See Clinical Studies (14.2) ] . Previously-Treated Urothelial Carcinoma Bavencio Is Indicated For The Treatment Of Patients With Locally Advanced Or Metastatic Urothelial Carcinoma (Uc) Who: Have Disease Progression During Or Following Platinum-Containing Chemotherapy Have Disease Progression Within 12 Months Of Neoadjuvant Or Adjuvant Treatment With Platinum-Containing Chemotherapy [See Clinical Studies (14.2) ]. 1.3 Advanced Renal Cell Carcinoma Bavencio In Combination With Axitinib Is Indicated For The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma (Rcc) [See Clinical Studies (14.3) ] .
|